Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review

Molecular genotyping for advanced solid malignancies has transformed the clinical management of patients with metastatic disease. Treatment decisions in a growing number of tumors require knowledge of molecularly driven alterations in order to select optimal targeted therapy. Although genomic testin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maisam Makarem, Miguel García-Pardo, Natasha B. Leighl
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	plasma genotyping ctDNA guideline recommendations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8efdeb04dad94efea67c4b5508660793
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8efdeb04dad94efea67c4b5508660793
record_format	dspace
spelling	oai:doaj.org-article:8efdeb04dad94efea67c4b55086607932021-11-11T15:27:37ZPlasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review10.3390/cancers132152992072-6694https://doaj.org/article/8efdeb04dad94efea67c4b55086607932021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5299https://doaj.org/toc/2072-6694Molecular genotyping for advanced solid malignancies has transformed the clinical management of patients with metastatic disease. Treatment decisions in a growing number of tumors require knowledge of molecularly driven alterations in order to select optimal targeted therapy. Although genomic testing of tumor tissue is the gold standard for identifying targetable genomic alterations, biopsy samples are often limited or difficult to access. This has paved the way for the development of plasma-based approaches for genomic profiling. Recent advances in the detection of plasma-circulating tumor DNA (ctDNA) have enabled the integration of plasma-based molecular profiling into clinical practice as an alternative or complementary tool for genomic testing in the setting of advanced cancer, to facilitate the identification of driver mutations to guide initial treatment and diagnose resistance. Several guidelines now recommend the use of plasma where tumor tissue is limited to identify a targetable genomic alteration. Current plasma-based assays can evaluate multiple genes in comprehensive panels, and their application in advanced disease will be increasingly incorporated into standard practice. This review focuses on current and future applications of plasma ctDNA-based assays in advanced solid malignancies, while highlighting some limitations in implementing this technology into clinical practice.Maisam MakaremMiguel García-PardoNatasha B. LeighlMDPI AGarticleplasma genotypingctDNAguideline recommendationsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5299, p 5299 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	plasma genotyping ctDNA guideline recommendations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	plasma genotyping ctDNA guideline recommendations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maisam Makarem Miguel García-Pardo Natasha B. Leighl Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
description	Molecular genotyping for advanced solid malignancies has transformed the clinical management of patients with metastatic disease. Treatment decisions in a growing number of tumors require knowledge of molecularly driven alterations in order to select optimal targeted therapy. Although genomic testing of tumor tissue is the gold standard for identifying targetable genomic alterations, biopsy samples are often limited or difficult to access. This has paved the way for the development of plasma-based approaches for genomic profiling. Recent advances in the detection of plasma-circulating tumor DNA (ctDNA) have enabled the integration of plasma-based molecular profiling into clinical practice as an alternative or complementary tool for genomic testing in the setting of advanced cancer, to facilitate the identification of driver mutations to guide initial treatment and diagnose resistance. Several guidelines now recommend the use of plasma where tumor tissue is limited to identify a targetable genomic alteration. Current plasma-based assays can evaluate multiple genes in comprehensive panels, and their application in advanced disease will be increasingly incorporated into standard practice. This review focuses on current and future applications of plasma ctDNA-based assays in advanced solid malignancies, while highlighting some limitations in implementing this technology into clinical practice.
format	article
author	Maisam Makarem Miguel García-Pardo Natasha B. Leighl
author_facet	Maisam Makarem Miguel García-Pardo Natasha B. Leighl
author_sort	Maisam Makarem
title	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
title_short	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
title_full	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
title_fullStr	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
title_full_unstemmed	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
title_sort	plasma-based genotyping in advanced solid tumors: a comprehensive review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8efdeb04dad94efea67c4b5508660793
work_keys_str_mv	AT maisammakarem plasmabasedgenotypinginadvancedsolidtumorsacomprehensivereview AT miguelgarciapardo plasmabasedgenotypinginadvancedsolidtumorsacomprehensivereview AT natashableighl plasmabasedgenotypinginadvancedsolidtumorsacomprehensivereview
_version_	1718435251896713216

Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review

Ejemplares similares